These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Thermo Fisher Scientific, the world leader in serving science, today announced that the Regeneron Genetics Center® (RGC™) has selected the Olink Explore HT proteomics platform for a large-scale ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

A COPD treatment for former smokers developed by Regeneron Pharmaceuticals and Sanofi failed to meet its primary endpoint in ...

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...